Median OS and 1-year or 2-year survival rate in our study were lower than those reported from previous clinical trials in GBM patients including RT-TMZ [11], Dose-Dense (DD) TMZ [41], TMZ+TTFields (Novo-TTF device) [42], BEV [27], BEV+RT-TMZ [26] or Rindopepimut/GM-CSF (no results available) (Supplementary Table 1). The gene discussed is CSF2; the disease is glioblastoma.